GCP
VKTX icon

GSA Capital Partners’s Viking Therapeutics VKTX Stock Holding History

GSA Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
25,988
+14,160
+120% +$457K 0.06% 497
2026
Q1 		$385K Sell
11,828
-20,094
-63% -$646K 0.02% 1086
2025
Q4 		$1.12M Buy
31,922
+16,237
+104% +$575K 0.1% 301
2025
Q3 		$412K Sell
15,685
-5,598
-26% -$167K 0.03% 983
2025
Q2 		$564K Buy
+21,283
New +$560K 0.04% 837
2025
Q1 		– Sell
-5,522
Closed -$222K – 2106
2024
Q4 		$222K Sell
5,522
-2,638
-32% -$150K 0.02% 1367
2024
Q3 		$517K Buy
8,160
+3,202
+65% +$188K 0.04% 878
2024
Q2 		$263K Buy
+4,958
New +$325K 0.02% 1341
2024
Q1 		– Sell
-68,415
Closed -$1.27M – 1994
2023
Q4 		$1.27M Sell
68,415
-21,326
-24% -$279K 0.11% 278
2023
Q3 		$993K Buy
89,741
+29,319
+49% +$419K 0.09% 401
2023
Q2 		$979K Sell
60,422
-55,618
-48% -$1.17M 0.1% 325
2023
Q1 		$1.93M Sell
116,040
-99,611
-46% -$1.03M 0.19% 79
2022
Q4 		$2.03M Sell
215,651
-5,832
-3% -$26K 0.25% 27
2022
Q3 		$602K Buy
221,483
+54,127
+32% +$177K 0.08% 441
2022
Q2 		$484K Buy
167,356
+27,692
+20% +$68.5K 0.07% 525
2022
Q1 		$419K Buy
139,664
+62,964
+82% +$226K 0.06% 658
2021
Q4 		$353K Buy
76,700
+23,122
+43% +$130K 0.04% 826
2021
Q3 		$336K Buy
53,578
+19,618
+58% +$121K 0.03% 945
2021
Q2 		$203K Sell
33,960
-25,681
-43% -$152K 0.02% 1179
2021
Q1 		$377K Sell
59,641
-13,458
-18% -$94.7K 0.06% 511
2020
Q4 		$412K Buy
73,099
+62,198
+571% +$377K 0.07% 546
2020
Q3 		$63K Buy
+10,901
New +$75.1K 0.01% 1174
2019
Q1 		– Sell
-13,507
Closed -$103K – 1712
2018
Q4 		$103K Sell
13,507
-7,593
-36% -$90.8K 0.01% 1217
2018
Q3 		$368K Sell
21,100
-35,200
-63% -$419K 0.02% 1229
2018
Q2 		$534K Buy
+56,300
New +$374K 0.03% 1127

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

GSA Capital Partners's VKTX Position: Q2 2026 in Review

GSA Capital Partners increased its Viking Therapeutics (VKTX) stake by 120% in Q2 2026, buying an estimated $457K and bringing the position to 25,988 shares worth $1.01M. The position accounts for 0.06% of the portfolio, ranked #497.

GSA Capital Partners first reported a position in VKTX in Q2 2018 and has held it in 25 quarters since. The position peaked at $2.03M in Q4 2022. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • GSA Capital Partners held 25,988 shares of Viking Therapeutics worth $1.01M as of Q2 2026.
  • GSA Capital Partners bought 14,160 Viking Therapeutics shares in Q2 2026, an estimated $457K.
  • Viking Therapeutics made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #497 holding.
  • GSA Capital Partners first reported a position in Viking Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • GSA Capital Partners's Viking Therapeutics position peaked at $2.03M in Q4 2022.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.